When U.S. Defense Secretary Lloyd Austin was diagnosed with prostate cancer, his illness was largely kept quiet from the public. Though Austin faced scrutiny for not being more forthcoming about his health, experts like Daniela Wittmann Ph.D., L.M.S.W. say prostate cancer is often difficult for men to discuss openly.
University of Michigan Rogel Cancer Center researcher Arul Chinnaiyan, M.D., Ph.D., has received a $5 million grant from the J.C. Kennedy Foundation to conduct laboratory tests of a potential drug candidate targeting a master regulator that controls the majority of genes involved in the most challenging type of prostate cancer.
Abhijit Parolia, M.S., Ph.D., assistant professor of pathology and urology at the University of Michigan Health Rogel Cancer Center, was named at NextGen Star by the American Association of Cancer Research.
After multiple rounds of treatments for his metastatic castration resistant prostate cancer, Donald Reynolds learned there were no more treatment options. Then he learned about a research study at the Rogel Cancer Center for Pluvicto, a radioactive drug treatment for metastatic castration resistant prostate cancer.
Within the last few years, nuclear medicine has added to cutting edge treatment options for cancer. One of the latest advancements is the use of a treatment called Pluvicto to treat metastatic castration-resistant prostate cancer.
MENU
